Related Experiment Videos
[Possibility probe on glucocorticoid treating primary child epistaxis]
Xinmao Xu1, Yalin Ma, Xindong Zhang
1Department of Otolaryngology, Tengzhou Central People's Hospital, Shandong Province, Tengzhou, 277500, China. xinmaoxu@163.com
Lin Chuang Er Bi Yan Hou Ke Za Zhi = Journal of Clinical Otorhinolaryngology
|June 7, 2005
Summary
Glucocorticoids (GCD) effectively treat childhood epistaxis by reducing nasal inflammation. This study found a strong link between allergic rhinitis and nosebleeds in children, with GCD promoting faster healing.
Area of Science:
- Otorhinolaryngology
- Pediatric Medicine
- Immunology
Context:
- Childhood epistaxis (PCE) is a common pediatric concern.
- Allergic rhinitis is increasingly recognized as a contributing factor to epistaxis in children.
- Current treatments for PCE lack specific anti-inflammatory approaches.
Purpose:
- To evaluate the efficacy of glucocorticoids (GCD) in treating primary childhood epistaxis (PCE).
- To investigate the association between nasal allergic reactions and PCE.
- To assess the impact of GCD on healing nasal septum mucosa erosion.
Summary:
- Rabbit models with induced nasal allergic reactions and mucosal erosion showed accelerated healing with dexamethasone compared to antibiotics.
- A survey of 1000 schoolchildren revealed a significantly higher incidence of epistaxis among those with allergic rhinitis.
- Clinical trials involving 200 children with epistaxis demonstrated superior outcomes in the dexamethasone treatment group versus the control group.
Impact:
- Establishes a strong correlation between allergic rhinitis and childhood epistaxis.
- Highlights the therapeutic potential of GCD in managing PCE by targeting underlying allergic inflammation.
- Provides evidence for GCD as a promising treatment to promote healing of the nasal septum mucosa in pediatric patients.